The impact of treatment with guselumab on adult patients up to 65 years with psoriasis and arthritis secondary to psoriasis: a narrative review of the literature

UMA REVISÃO NARRATIVA DE LITERATURA

Abstract

Introduction. Guselkumab (Tremfya®) is an injectable solution used to treat moderate to severe psoriasis and is recommended for patients who are candidates for systemic treatment or phototherapy [1]. It is an immunosuppressive medication that acts on the cytokine IL-23, involved in the regulation of the inflammatory response [2]. Being a new medication, there is an opportunity to carry out a review without bias, in addition to exposing those present in the selected articles. Goal.  To analyze the impact of treatment in adults up to 65 years of age with psoriasis or psoriatic arthritis, addressing appropriate storage and administration to optimize efficacy, in addition to evaluating long-term safety and associated risks. An assessment of the clinical response and effectiveness in treating these conditions will also be carried out. Methodology: The VHL and PubMed databases were used, with specific filters to select articles. Due to the scarcity of literature, adolescents and pediatric patients were excluded from the analysis. The leaflet and regulations by ANVISA were obtained online. Discussion: Guselkumab demonstrated efficacy in inhibiting IL-23, standing out as a safe and effective long-term option [3]. The possibility of being an effective alternative for patients refractory to other therapies was observed, and could positively influence future clinical outcomes [4]. Conclusion: Guselkumab proves to be an effective alternative in the treatment of psoriasis and psoriatic arthritis in adults. However, there are no specific results for the Brazilian population, as well as for the elderly and pediatric patients. Furthermore, some of the studies used received funding from the pharmaceutical industry, imposing a bias on the results.